Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03329950 · ClinicalTrials.gov registry record · Phase 1
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
A Phase 1 study, sponsored by Celldex Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 132
- Enrollment target
NCT03329950 is a Phase 1 study that has completed, run by Celldex Therapeutics. The registered enrollment target is 132 participants.
The verdict
NCT03329950, a Phase 1 study, has completed, sponsored by Celldex Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 132 participants
- Enrollment target
Study Summary
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.
Interventions
- DRUG pembrolizumab
- DRUG Chemotherapy
- DRUG CDX-1140
- DRUG CDX-301
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2022-09-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03329950
The ClinicalTrials.gov registry entry for NCT03329950 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which pembrolizumab is the first listed.
NCT03329950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03329950 about?
NCT03329950 is a clinical study titled "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies". This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.
What is the current status of trial NCT03329950?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2017-12-01. Estimated completion is 2022-09-13.
What interventions are being tested in trial NCT03329950?
The interventions under investigation include: pembrolizumab (DRUG), Chemotherapy (DRUG), CDX-1140 (DRUG), CDX-301 (DRUG).
Who is sponsoring clinical trial NCT03329950?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.